Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561031 | 0.92 | TP53 (0.54) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL4560573 | 0.85 | ALDH1A1 (0.51) | LMNATP53ALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL9321117 | 0.83 | ALDH1A1 (0.61) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL11815719 | 0.81 | ALDH1A1 (0.59) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL4558955 | 0.81 | ALDH1A1 (0.50) | LMNATP53ALDH1A1SMN1; SMN2LTB4R2 | |
| SCHEMBL23086144 | 0.79 | CES2 (0.49) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL28367202 | 0.79 | CES2 (0.49) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL11784549 | 0.79 | CES2 (0.49) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL30404353 | 0.79 | CES2 (0.49) | LMNATP53ALDH1A1SMN1; SMN2CES2 | |
| SCHEMBL5696562 | 0.78 | SMN1; SMN2 (0.49) | LMNATP53ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | LMNA 424/4885TP53 1559/4885ALDH1A1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.